Non-Hodgkin's lymphoma and the CNS: Prophylaxis and therapy in immunocompetent and HIV-positive individuals

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 335-341

  Mazhar, Danish ^a   Stebbing, Justin ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cerebrospinal fluid; Depocyte; Intrathecal; Lymphoma

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; LIPOSOME; METHOTREXATE; PREDNISOLONE; RITUXIMAB; THIOTEPA; VINCRISTINE; VINDESINE; ANTINEOPLASTIC ANTIMETABOLITE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CONTROL; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOPROPHYLAXIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE ASSOCIATION; ENCAPSULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOCOMPETENCE; MENINGIOMA; NONHODGKIN LYMPHOMA; REVIEW; SURVIVAL TIME; SUSTAINED RELEASE FORMULATION; TREATMENT PLANNING; WHOLE BODY RADIATION; ALGORITHM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOLOGY; PROGNOSIS;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYTARABINE; HIV INFECTIONS; HUMANS; IMMUNOCOMPETENCE; LYMPHOMA, NON-HODGKIN; PROGNOSIS;

EID: 33644895130     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.335     Document Type: Review

References (59)

1. Bleyer WA, Byrne TN. Leptomeningeal cancer in leukemia and solid tumors. Curr. Probl. Cancer 12, 181-238 (1988).
2. Bleyer WA. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin. Cancer Res. 5, 3349-3351 (1999).
3. Montoto S, Lister TA. Secondary central nervous system lymphoma: risk factors and prophylaxis. Hematol. Oncol. Clin. North Am. 19, 751-763 (2005).
4. Kuo AH, Yataganas X, Galicich JH, Fried J, Clarkson BD. Proliferative kinetics of central nervous system (CNS). Leukemia Cancer 36, 232-239 (1975).
5. Oshiro EM, Viola JJ, Oldfield EH et al. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther. 2, 87-95 (1995).
6. Greenfield JP, Bilsky MH. Neurosurgical interventions for leptomeningeal tumor. Cancer Treat. Res. 125, 107-119 (2005).
7. Litam JP, Cabanillas F, Smith TL, Bodey GP, Freireich EJ. Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood 54, 1249-1257 (1979).
8. van Besien K, Ha CS, Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91, 1178-1184 (1998).
9. Cheung CW, Burton C, Smith P, Linch DC, Hoskin PJ, Ardeshna KM. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br. J. Haematol. 131, 193-200 (2005).
10. Ersboll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand. J. Haematol. 35, 487-496 (1985).
11. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol. Oncol. 8, 141-145 (1990).
12. Hollender A, Kvaloy S, Lote K, Nome O, Holte H. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur. J. Cancer 36, 1762-1768 (2000).
13. Tomita N, Kodama F, Sakai R et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk. Lymphoma 38, 335-343 (2000).
14. Keldsen N, Michalski W, Bentzen SM, Hansen KB, Thorling K. Risk factors for central nervous system involvement in non-Hodgkin's-lymphoma - a multivariate analysis. Acta Oncol. 35, 703-708 (1996).
15. Bollen EL, Brouwer RE, Hamers S et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch. Neurol. 54, 854-859 (1997).
16. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 104, 3009-3020 (2004).
17. Bashir RM, Bierman PJ, Vose JM, Weisenburger DD, Armitage JO. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am. J. Clin. Oncol. 14, 478-482 (1991).
18. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J. Clin. Oncol. 21, 20-27 (2003).
19. Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk. Lymphoma 44, 1173-1178 (2003).
20. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann. Hematol. 85, 45-50 (2006).
21. Pui CH, Mahmoud HH, Rivera GK et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92, 411-415 (1998).
22. Recht L, Straus DJ, Cirrincione C. Thaler HT, Posner JB. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am. J. Med. 84, 425-435 (1988).
23. Chua SL, Seymour JF, Streater J, Wolf MM, Januszewicz EH, Prince HM. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 43, 1783-1788 (2002).
24. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann. Oncol. 11, 685-690 (2000).
25. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102, 4284-4289 (2003).
26. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 235-242 (2002).
27. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann. Oncol. 15, 129-133 (2004).
28. Bower M, Gazzard B, Mandalia S et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann. Intern. Med. 143, 265-273 (2005).
29. Seale JR. Not again! Erroneous intrathecal injection results from a problem with protocols. BMJ 322, 548 (2001).
30. Dyer C. Doctor's manslaughter trial halted owing to defendant's health. BMJ 327, 123 (2003).
31. Kim S, Kim DJ, Geyer MA, Howell SB. Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res. 47, 3935-3937 (1987).
32. Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann. Pharmacother. 34, 1173-1178 (2000).
33. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics. Clin. Pharmacol. Ther. 35, 826-830 (1984).
34. Kim S, Khatibi S, Howell SB, McCully C, Balis FM, Poplack DG. Prolongation of drug exposure in cerebrospinal fluid by encapsulation into DepoFoam. Cancer Res. 53, 1596-1598 (1993).
35. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch. Neurol. 52, 912-917 (1995).
36. Mazhar and colleagues. In press Blood (2006).
37. Glantz MJ, LaFollette S, Jaeckle KA et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin. Oncol. 17, 3110-3116 (1999).
38. Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5, 3394-3402 (1999).
39. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 97, 3053-3060 (2003).
40. Sarker D, Thirlwell C, Nelson M, Gazzard B, Bower M. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 17, 861-865 (2003).
41. Yeni PG, Hammer SM, Carpenter CC et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288, 222-235 (2002).
42. Ickovics JR, Meade CS. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care 14, 309-318 (2002).
43. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353, 487-497 (2005).
44. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 329, 987-994 (1993).
45. Kaplan LD, Straus DJ, Testa MA et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N. Engl. J. Med. 336, 1641-1648 (1997).
46. Bower M, Stern S, Fife K, Nelson M, Gazzard BG. Weekly alternating combination chemotherapy for good prognosis AIDS- related lymphoma. Eur. J. Cancer 36, 363-367 (2000).
47. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J. Clin. Oncol. 19, 2171-2178 (2001).
48. Navarro JT, Ribera JM, Oriol A et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br. J. Haematol. 112, 909-915 (2001).
49. Antinori A, Cingolani A, Alba L et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 15, 1483-1491 (2001).
50. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91, 155-163 (2001).
51. Little RF, Pittaluga S, Grant N et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 101, 4653-4659 (2003).
52. Sparano JA, Lee S, Chen MG et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group trial (E1494). J. Clin. Oncol. 22, 1491-1500 (2004).
53. Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J. Clin. Oncol. 22, 2662-2670 (2004).
54. Bower M, McCall-Peat N, Ryan N et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104, 2943-2946 (2004).
55. Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 Phase II trials. Blood 105, 1891-1897 (2005).
56. Kaplan LD, Lee JY, Ambinder RF et al. Rituximab does not improve clinical outcome in a randomized Phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106, 1538-1543 (2005).
57. Lascaux AS, Hemery F, Goujard C et al. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res. Hum. Retroviruses 21, 214-220 (2005).
58. Sawka CA, Shepherd FA, Franssen E et al. A Prospective, non-randomised Phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. Biotechnol. Annu. Rev. 11, 381-389 (2005).
59. Mazhar D, Stebbing J, Lewis R, Nelson M, Gazzard BG, Bower M. The management of meningeal lymphoma in patients with HIV in the era of HAART: intrathecal depot cytarabine is effective and safe. Blood (2006) (In press).